Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Tag: Clinical trial
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
Amgen’s Kyprolis, J&J’s Darzalex team up on myeloma survival win
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data
New clinical trial with cyclodextrins on hernia treatment
A new clinical trial with a rather innovative use of cyclodextrins is about to start shortly, although the recruitment has
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol
Clinical trial on Noninfectious Anterior Uveitis – SBECD offering disease resolution
Aldeyra Therapeutics Announced Results from the SOLACE Trial in Noninfectious Anterior Uveitis. The main points are: Statistical Significance Not Achieved
The Use of ADV6209 for Premedication in Pediatric Anesthesia
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today